Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2019-01-23 Capital/Financing Update
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
BIOCARTIS SUCCESSFULLY RAISES EUR 55.50 MILLION IN AN EQUITY PLACEMENT
Capital/Financing Update Classification · 99% confidence The document is a press release announcing that Biocartis Group NV successfully raised EUR 55.50 million through a private placement (accelerated bookbuild offering) of new shares. Key phrases include "successfully raises EUR 55.50 million in an equity placement," "private placement via an accelerated bookbuild offering," and details about the increase in share capital. This activity directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (14,383 chars), confirming it is the primary announcement, not just a brief RPA.
2019-01-23 English
BIOCARTIS HAALT EUR 55,50 MILJOEN OP VIA SUCCESVOLLE KAPITAALVERHOGING
Capital/Financing Update Classification · 99% confidence The document is a press release (PERSBERICHT) dated January 23, 2019, announcing that Biocartis successfully raised EUR 55.50 million through a private placement of new shares. The text explicitly details the capital increase, the issuance price, the number of new shares, the intended use of proceeds (financing expansion, sales, production capacity), and the resulting increase in the total number of outstanding shares (from 51,361,088 to 56,361,088). This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific corporate financing event.
2019-01-23 Dutch
BIOCARTIS UPSIZES ITS EQUITY PLACEMENT DUE TO SIGNIFICANT DEMAND
Capital/Financing Update Classification · 99% confidence The document is a press release announcing that Biocartis Group NV is 'upsizing its equity placement' from EUR 45 million to EUR 55 million via an 'accelerated bookbuild offering'. This action directly relates to fundraising, financing activities, and changes in the company's capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is the primary announcement detailing the financing event, CAP is the most appropriate classification.
2019-01-23 English
BIOCARTIS VERHOOGT HET BEDRAG VAN DE KAPITAALVERHOGING WEGENS STERKE VRAAG
Capital/Financing Update Classification · 99% confidence The document is a press release written in Dutch announcing that Biocartis Group NV is increasing the size of its previously announced capital increase (kapitaalverhoging) from EUR 45 million to approximately EUR 55 million, organized via a private placement with an accelerated book-building procedure. This action directly relates to fundraising, financing activities, and changes in the company's capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), but the substance of the financing event itself.
2019-01-23 Dutch
Biocartis launches equity placement
Capital/Financing Update Classification · 99% confidence The document is a press release titled "BIOCARTIS LAUNCHES EQUITY PLACEMENT" announcing an offering to raise approximately EUR 45 million via a private placement through an accelerated bookbuild. This activity directly relates to the company raising new capital and changing its capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2019-01-23 English
Biocartis lanceert kapitaalverhoging
Capital/Financing Update Classification · 99% confidence The document is a press release titled "BIOCARTIS LANCEERT KAPITAALVERHOGING" (Biocartis Launches Capital Increase). It explicitly details the launch of a capital increase via a private placement to raise approximately EUR 45 million. This activity directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is a primary announcement, not a report about a past event, ruling out RPA or ER.
2019-01-23 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.